Modality
Degrader
MOA
CFTRmod
Target
TROP-2
Pathway
Epigenetic
Hemophilia AOvarian Ca
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
Apr 2019
→ Sep 2025
Phase 1Current
NCT03033765
1,451 pts·Ovarian Ca
2019-04→2025-09·Terminated
1,451 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-09-047mo agoPh2 Data· Ovarian Ca
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2025-09-04 · 7mo ago
Ovarian Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03033765 | Phase 1/2 | Ovarian Ca | Terminated | 1451 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 |